Table 1 Baseline characteristics
All | Paracetamol | Control | Metoclopramide | Control | Ceftriaxone | Control | |
|---|---|---|---|---|---|---|---|
Total patients randomised | |||||||
Age (years) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
Sex, male (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Premorbid mRS [/6] | Median [IQR] | Median [IQR] | Median [IQR] | Median [IQR] | Median [IQR] | Median [IQR] | Median [IQR] |
Ethnicity, white (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Medical history (%) | |||||||
Atrial fibrillation | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Hypercholesterolaemia | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Hypertension | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Diabetes mellitus | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Obstructive pulmonary disease | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Previous stroke | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Immunocompromised | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Smoking, current | |||||||
Never | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Ever | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Currently | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Pre-stroke method of food intake | |||||||
Normal food | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Oral softened food or fluids only | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Nasogastric tube | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Percutaneous endoscopic gastrostomy | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Intravenous only | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Use of drugs 3 days before randomisation | |||||||
Paracetamol | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Metoclopramide | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Ceftriaxone | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Time, onset to randomisation (min) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
Stroke type (%) | |||||||
Ischaemic stroke | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Intracerebral haemorrhage | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Other diagnosis | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
NIHSS (/42) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
Systolic BP (mmHg) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
Diastolic BP (mmHg) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
Heart rate (bpm) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
Body temperature (°C) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
Acute stroke treatment (%) | |||||||
Intravenous thrombolysis | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
Mechanical thrombectomy | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |